Modus Operandi

» immunology, disease/medicine and nanotechnology

Most Recent

image: Bespoke Cell Jackets

Bespoke Cell Jackets

By | December 1, 2014

Scientists make hydrogel coats for individual cells that can be tailored to specific research questions.

0 Comments

image: Film Stars

Film Stars

By | June 1, 2014

Engineered bacteria can shape electricity-conducting nanowires.

0 Comments

image: Dead or Alive?

Dead or Alive?

By | June 1, 2013

Scientists create nontoxic pH nanosensors to assess viability of transplanted therapeutic cells.

0 Comments

image: BRET Meets FRET

BRET Meets FRET

By | May 1, 2013

Scientists create biocompatible, self-luminescing nanoparticles for in vivo imaging.

0 Comments

image: Mimicking Mussels

Mimicking Mussels

By | April 1, 2013

Scientists develop a gel that mimics mollusc glue to coat the insides of blood vessels.

1 Comment

image: The Inside Scoop

The Inside Scoop

By | September 1, 2012

Probing cells with nanometer-scale electrodes

0 Comments

image: Dynamic Delivery

Dynamic Delivery

By | July 1, 2012

Microscopic sponges made entirely of RNA enable efficient gene silencing.

0 Comments

image: Switching the Bait

Switching the Bait

By | February 1, 2012

Turning a standard technique into an unbiased screen for diagnostic biomarkers

6 Comments

image: Flow Cytometry for the Masses

Flow Cytometry for the Masses

By | December 1, 2011

Tagging antibodies with rare earth metals instead of fluorescent molecules turns a veteran technique into a high-throughput powerhouse.

3 Comments

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham